| Dr Duane Chase, MD | |
|
1510 Plateau Dr, Gallup, NM 87301-5021 | |
| (505) 722-3100 | |
| (505) 722-3100 |
| Full Name | Dr Duane Chase |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 21 Years |
| Location | 1510 Plateau Dr, Gallup, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992844906 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 2004-0375 (New Mexico) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD2007-0779 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Gallup Indian Medical Center | Gallup, NM | Hospital |
| Crownpoint Phs Indian Hospital | Crownpoint, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dhhs Phs Naihs Crownpoint Hospital | 0143128041 | 37 |
| Woodrow Wilson Keeble Memorial Health Care Center | 1850295940 | 14 |
| Dhhs,phs,naihs, Gallup Indian Medical Center | 3173436409 | 100 |
News Archive
Coma patients in ICU, e.g. after cardiac arrest, have been targeted in research projects for many years. One of the key questions is how to predict the outcome after coma. Current approaches are often based on qualitative assessment of electroencephalogram (EEG) patterns.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.
GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.
› Verified 4 days ago
| Entity Name | Us Health Dept Of Health & Human Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972694602 PECOS PAC ID: 9638081623 Enrollment ID: O20031106000399 |
News Archive
Coma patients in ICU, e.g. after cardiac arrest, have been targeted in research projects for many years. One of the key questions is how to predict the outcome after coma. Current approaches are often based on qualitative assessment of electroencephalogram (EEG) patterns.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.
GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.
› Verified 4 days ago
| Entity Name | Dhhs,phs,naihs, Gallup Indian Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225002322 PECOS PAC ID: 3173436409 Enrollment ID: O20031111000840 |
News Archive
Coma patients in ICU, e.g. after cardiac arrest, have been targeted in research projects for many years. One of the key questions is how to predict the outcome after coma. Current approaches are often based on qualitative assessment of electroencephalogram (EEG) patterns.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.
GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.
› Verified 4 days ago
| Entity Name | Woodrow Wilson Keeble Memorial Health Care Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366471666 PECOS PAC ID: 1850295940 Enrollment ID: O20031120000810 |
News Archive
Coma patients in ICU, e.g. after cardiac arrest, have been targeted in research projects for many years. One of the key questions is how to predict the outcome after coma. Current approaches are often based on qualitative assessment of electroencephalogram (EEG) patterns.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.
GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.
› Verified 4 days ago
| Entity Name | Dhhs Phs Naihs Crownpoint Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114960093 PECOS PAC ID: 0143128041 Enrollment ID: O20031230000393 |
News Archive
Coma patients in ICU, e.g. after cardiac arrest, have been targeted in research projects for many years. One of the key questions is how to predict the outcome after coma. Current approaches are often based on qualitative assessment of electroencephalogram (EEG) patterns.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.
GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.
› Verified 4 days ago
| Entity Name | Micmac Service Unit |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831312313 PECOS PAC ID: 3072608553 Enrollment ID: O20070927001066 |
News Archive
Coma patients in ICU, e.g. after cardiac arrest, have been targeted in research projects for many years. One of the key questions is how to predict the outcome after coma. Current approaches are often based on qualitative assessment of electroencephalogram (EEG) patterns.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.
GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.
› Verified 4 days ago
| Entity Name | Catawba Services Unit-indian Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467485540 PECOS PAC ID: 4284880204 Enrollment ID: O20120807000824 |
News Archive
Coma patients in ICU, e.g. after cardiac arrest, have been targeted in research projects for many years. One of the key questions is how to predict the outcome after coma. Current approaches are often based on qualitative assessment of electroencephalogram (EEG) patterns.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.
GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Duane Chase, MD 1510 Plateau Dr, Gallup, NM 87301-5021 Ph: (505) 722-3100 | Dr Duane Chase, MD 1510 Plateau Dr, Gallup, NM 87301-5021 Ph: (505) 722-3100 |
News Archive
Coma patients in ICU, e.g. after cardiac arrest, have been targeted in research projects for many years. One of the key questions is how to predict the outcome after coma. Current approaches are often based on qualitative assessment of electroencephalogram (EEG) patterns.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.
GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.
› Verified 4 days ago
Richard Kim Laughter, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1500 S Second St Ste A, Gallup, NM 87301 Phone: 505-722-2923 Fax: 505-722-2961 | |
Flor J. Caballar Gonzaga, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1211 E Aztec Ave, Gallup, NM 87301 Phone: 505-863-1820 | |
Mrs. Chitra Bhandari, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 516 Nizhoni Blvd, Gallup, NM 87301 Phone: 505-722-1000 Fax: 505-722-1396 | |
Kate Measom, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 516 E Nizhoni Blvd, Gallup, NM 87301 Phone: 505-722-1000 |